Regional anesthesia has demonstrated better post-operative analgesia, decreased opioid consumption and length of stay, early rehabilitation, fewer anesthesia-related side effects and high patient satisfaction compared to general anesthesia1,2. A joint statement from the American Society of Regional Anesthesia and Pain Medicine (ASRA) and the European Society of Regional Anaesthesia and Pain Therapy (ESRA) recommend regional anesthesia over general anesthesia for COVID-19 patients where possible to reduce transmission of the virus.

GIVING ANESTHESIOLOGISTS CONTROL: A Groundbreaking New Technology for Regional Anesthesia

SAFIRA® – SAFer Injection for Regional Anaesthesia.

SAFIRA makes regional anesthesia a one person procedure, putting control in the hands of the anesthesiologist. Engineered with safety in mind, SAFIRA is a unique solution which monitors and limits injection pressure. This improves patient safety by reducing the risk of nerve damage resulting from the regional anesthesia procedure. SAFIRA helps promote better outcomes for both healthcare providers and patients.

  • Creates a single operator procedure
  • Engineered safety solution to control injection pressure threshold
  • Reduces chances of nerve injury
  • Improves patient safety
©2014 Konica Minolta Healthcare Americas, Inc.